Insitro was founded in 2018 by Daphne Koller. The company has not publicly endorsed plans to participate in an IPO.
Insitro is an AI-powered drug development company. Board member Dr. Roger Perlmutter describes the three pillars of the company's approach as, "Target identification, lead discovery, and the elaboration of highly evolved therapeutic candidates." Insitro has raised more than $600 million in venture capital funding from investors including CPP Investments, Andreessen Horowitz, T. Rowe Price Associates, Casdin Capital, Temasek, and Softbank Investment Advisors. The company did not disclose valuation figures following a $400 million Series C fundraising round in 2021.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/15/2021 | Series C | $400MM | $xx.xx | $2.57B | CPP Investments, Andreessen Horowitz, T. Rowe Price, Casdin Capital, BlackRock, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital, Alexandria Venture Investments, Temasek, Softbank | |
Price per Share
$xx.xx
Shares Outstanding
21,868,541
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
CPP Investments, Andreessen Horowitz, T. Rowe Price, Casdin Capital, BlackRock, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital, Alexandria Venture Investments, Temasek, Softbank
|
||||||
05/26/2020 | Series B | $149.22MM | $xx.xx | $725.03MM | Andreessen Horowitz, CPP Investments, T. Rowe Price, BlackRock, Casdin Capital, HOF Capital, WuXi AppTec, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, Alexandria Venture Investments | |
Price per Share
$xx.xx
Shares Outstanding
23,949,729
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Andreessen Horowitz, CPP Investments, T. Rowe Price, BlackRock, Casdin Capital, HOF Capital, WuXi AppTec, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, Alexandria Venture Investments
|
||||||
05/01/2018 | Series A-2 | $49.41MM | $xx.xx | $309.11MM | a16z, Arch Venture, Foresite Capital, GV, Third Rock Ventures, Alexandria Venture, Bezos Expeditions, Mubadala Investment Company, Two Sigma Ventures, Verily | |
Price per Share
$xx.xx
Shares Outstanding
18,359,806
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
a16z, Arch Venture, Foresite Capital, GV, Third Rock Ventures, Alexandria Venture, Bezos Expeditions, Mubadala Investment Company, Two Sigma Ventures, Verily
|
||||||
05/01/2018 | Series A-1 | $30MM | $xx.xx | $309.11MM | a16z, Arch Venture, Foresite Capital, GV, Third Rock Ventures, Alexandria Venture, Bezos Expeditions, Mubadala Investment Company, Two Sigma Ventures, Verily | |
Price per Share
$xx.xx
Shares Outstanding
33,327,366
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
a16z, Arch Venture, Foresite Capital, GV, Third Rock Ventures, Alexandria Venture, Bezos Expeditions, Mubadala Investment Company, Two Sigma Ventures, Verily
|